Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomised pilot feasibility study of eye movement desensitisation and reprocessing recent traumatic episode protocol, to improve psychological recovery following intensive care admission for COVID-19.
Bates A, Golding H, Rushbrook S, Shapiro E, Pattison N, Baldwin DS, Grocott MPW, Cusack R. Bates A, et al. Among authors: rushbrook s. J Intensive Care Soc. 2023 Aug;24(3):309-319. doi: 10.1177/17511437221136828. Epub 2022 Nov 19. J Intensive Care Soc. 2023. PMID: 37744073 Free PMC article.
CovEMERALD: Assessing the feasibility and preliminary effectiveness of remotely delivered Eye Movement Desensitisation and Reprocessing following Covid-19 related critical illness: A structured summary of a study protocol for a randomised controlled trial.
Bates A, Rushbrook S, Shapiro E, Grocott M, Cusack R. Bates A, et al. Among authors: rushbrook s. Trials. 2020 Nov 17;21(1):929. doi: 10.1186/s13063-020-04805-1. Trials. 2020. PMID: 33203440 Free PMC article.
Mixed-methods randomised study exploring the feasibility and acceptability of eye-movement desensitisation and reprocessing for improving the mental health of traumatised survivors of intensive care following hospital discharge: protocol.
Bates A, Golding H, Rushbrook S, Highfield J, Pattison N, Baldwin D, Grocott MPW, Cusack R. Bates A, et al. Among authors: rushbrook s. BMJ Open. 2024 Jan 29;14(1):e081969. doi: 10.1136/bmjopen-2023-081969. BMJ Open. 2024. PMID: 38286705 Free PMC article.
Refractory depression - mechanisms and efficacy of radically open dialectical behaviour therapy (RefraMED): findings of a randomised trial on benefits and harms.
Lynch TR, Hempel RJ, Whalley B, Byford S, Chamba R, Clarke P, Clarke S, Kingdon DG, O'Mahen H, Remington B, Rushbrook SC, Shearer J, Stanton M, Swales M, Watkins A, Russell IT. Lynch TR, et al. Among authors: rushbrook sc. Br J Psychiatry. 2020 Apr;216(4):204-212. doi: 10.1192/bjp.2019.53. Br J Psychiatry. 2020. PMID: 31317843 Free PMC article. Clinical Trial.
Refractory depression - cost-effectiveness of radically open dialectical behaviour therapy: findings of economic evaluation of RefraMED trial.
Shearer J, Lynch TR, Chamba R, Clarke S, Hempel RJ, Kingdon DG, O'Mahen H, Remington B, Rushbrook SC, Russell IT, Stanton M, Swales M, Watkins A, Whalley B, Byford S. Shearer J, et al. Among authors: rushbrook sc. BJPsych Open. 2019 Sep;5(5):e64. doi: 10.1192/bjo.2019.57. BJPsych Open. 2019. PMID: 31352916 Free PMC article.
H.O'M. reports personal fees outside the submitted work from the Charlie Waller Institute and Improving Access to Psychological Therapy. S.R. provides RO DBT supervision through her company S C Rushbrook Ltd. ...
H.O'M. reports personal fees outside the submitted work from the Charlie Waller Institute and Improving Access to Psychological Therapy. …
Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
Colapietro F, Maisonneuve P, Lytvyak E, Beuers U, Verdonk RC, van der Meer AJ, van Hoek B, Kuiken SD, Brouwer JT, Muratori P, Aghemo A, Carella F, van den Berg AP, Zachou K, Dalekos GN, Di Zeo-Sánchez DE, Robles M, Andrade RJ, Montano-Loza AJ, van den Brand FF, Slooter CD, Macedo G, Liberal R, de Boer YS, Lleo A; Dutch AIH Study Group; International Autoimmune Hepatitis Group. Colapietro F, et al. J Hepatol. 2024 Jan;80(1):53-61. doi: 10.1016/j.jhep.2023.09.010. Epub 2023 Oct 5. J Hepatol. 2024. PMID: 37802188
HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells.
Zecher BF, Ellinghaus D, Schloer S, Niehrs A, Padoan B, Baumdick ME, Yuki Y, Martin MP, Glow D, Schröder-Schwarz J, Niersch J, Brias S, Müller LM, Habermann R, Kretschmer P, Früh T, Dänekas J, Wehmeyer MH, Poch T, Sebode M; International PSC Study Group (IPSCSG); Ellinghaus E, Degenhardt F, Körner C, Hoelzemer A, Fehse B, Oldhafer KJ, Schumacher U, Sauter G, Carrington M, Franke A, Bunders MJ, Schramm C, Altfeld M. Zecher BF, et al. Gut. 2024 Jan 5;73(2):325-337. doi: 10.1136/gutjnl-2023-329524. Gut. 2024. PMID: 37788895 Free PMC article.
Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis.
Trainee Collaborative for Research and Audit in Hepatology UK. Electronic address: oliver.tavabie@nhs.net; Trainee Collaborative for Research and Audit in Hepatology UK. Trainee Collaborative for Research and Audit in Hepatology UK. Electronic address: oliver.tavabie@nhs.net, et al. J Hepatol. 2023 Oct;79(4):e165-e167. doi: 10.1016/j.jhep.2023.05.035. Epub 2023 Jun 12. J Hepatol. 2023. PMID: 37315808 No abstract available.
79 results